Well Referenced

Tag: Bevacizumab

Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals

This preclinical study evaluated the efficacy of convection-enhanced delivery (CED) of bevacizumab, alone or combined with irinotecan, in murine models bearing intracranial gliomas (U87 and U251 cell lines). CED-treated mice demonstrated a 30% longer survival compared to those receiving intravenous (IV) bevacizumab. The combination of CED bevacizumab and intraperitoneal irinotecan

Read More »
June 26, 2025 No Comments

Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials

This network meta-analysis synthesized data from nine phase III randomized controlled trials to assess the relative efficacy of various first-line systemic therapies for unresectable hepatocellular carcinoma (HCC). The study found that combinations of immune checkpoint inhibitors (ICIs) and anti-VEGF agents, particularly atezolizumab plus bevacizumab, demonstrated the most favorable outcomes in

Read More »
June 26, 2025 No Comments

A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)

This phase 3 randomized study evaluates the efficacy and safety of high-dose vitamin C in combination with FOLFOX ± bevacizumab in patients with unresectable, untreated metastatic colorectal cancer (CRC). The results suggest that the addition of vitamin C to standard chemotherapy may improve clinical outcomes by enhancing treatment response. However,

Read More »
June 26, 2025 No Comments